Hong Kong, 17 May 2023
Opharmic Achieves ISO 13485 Certification
Opharmic Technology (HK) Limited is proud to announce that it has achieved ISO 13485:2016 certification. This internationally recognized standard specifies requirements for a quality management system (QMS) in the design, development, production, and distribution of medical devices.
This certification marks a critical milestone in Opharmic’s journey toward commercialization, demonstrating the company’s commitment to the highest standards of quality, safety, and regulatory compliance. ISO 13485 certification is a key prerequisite for many regulatory approvals worldwide, including pathways toward clinical trials.
Since 2022, Opharmic has implemented a robust QMS that covers its flagship platforms: MeticTouch® for ultrasound drug delivery and MeticStim® for targeted cell stimulation. These platforms aim to provide safer, more effective, and patient-friendly solutions.
Achieving this certification involved rigorous internal process improvements, documentation, risk management, and audits. It reflects the dedication of the entire team in building a scalable and compliant organization capable of meeting stringent international medical device regulations.
“ISO 13485 certification is a testament to our team’s professionalism and our unwavering focus on quality and patient safety,” said Sarah Cheung, COO of Opharmic Technology. “This achievement strengthens our foundation as we advance our pipeline toward clinical studies and potential partnerships. It brings us one step closer to delivering transformative, non-invasive ultrasound solutions to patients and our partners.”
The company will continue to refine its quality systems and development processes to support future commercialization of its innovative ultrasound platforms.
Opharmic Technology